

HJA
13
8/13/01

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Batra et al.)
Serial No.: Not Yet Assigned)
(Continuation application of)
USSN 09/312,617)
Docket No.: 20243CA)
Express Mailed: June 29, 2001)
For: "COMPRESSED TABLET FORMULATION")

Examiner:
Not Yet Assigned

Previous Examiner:
Sharareh, S.

Art Unit: Not yet assigned

Previous Art Unit:

Box PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

F03290-126460

EXPRESS MAIL CERTIFICATE	DATE OF DEPOSIT	June 28, 2001
EXPRESS MAIL NO.	DE15231045865	6/28/01
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL, "POST OFFICE TO ADDRESSEE" BEFORE 6 P.M. ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231. J. J. [Signature] MAIL DAY		

3/31/04

Sir:

Applicants request entry of this amendment prior to examination of the above-identified application, which is a Rule 53(b) continuation of USSN 09/312,617. Please amend the above-identified application as follows:

IN THE SPECIFICATION:

Please insert the following paragraph on page 1 after the Title:

A1 -- This application is a continuation of US Serial No. 09/312,617, filed January 17, 2001, which is a continued prosecution application under 37 C.F.R. § 1.53(d) of US Serial No. 09/312,617, filed May 17, 1999, now abandoned, which claims the benefit of US Provisional Application No. 60/086,921, filed May 27, 1998.--

Replace the fourth paragraph on page 7 with the following paragraph:

A2 -- The formulation also is bioequivalent to a capsule with a smaller dose (200 mg), and more bioavailable than other tablet compositions. The advantages over the capsule include robust processing and sorting steps, smaller size with a larger dose, and market preference. The